ePro and Diabetes

•

1 gostou•300 visualizações

Chris Teel Hall

Diabetes clinical research often includes PROs to measure symptoms and safety, evaluate quality of life, and record the economic burden. This edition of Insights highlights the conversion from paper to PRO for a PRO instrument designed to assess the impact of diabetes on the quality of life of patients with diabetes.

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

ePro and Diabetes

Mais conteúdo relacionado

Destaque

Temptation

Electronic Source (eSource) Data: Defined and Interpreted by Global Regulatory Authorities Two recent regulatory publications from FDA and EMA address the topic of electronic source data in clinical investigations. While the views are slightly different, these documents provide clarity concerning the expectations of regulatory authorities regarding electronic source data. This Issue explores the topic of electronic source data and identifies some key concepts that are common (and seemingly agreed upon) within these publications.

eSource Data and ePRO

eSource Data and ePRO

eSource Data and ePRO

Chris Teel Hall

Changing Paradigms - The Evolution of Experiential Production

Changing Paradigms - The Evolution of Experiential Production

Changing Paradigms - The Evolution of Experiential Production

ePRO Archives

Chris Teel Hall

$Glenn\'s Production work$ $Glenn\'s Production work$

Glenn\'s Production work

The PRO Final Guidance announced December 2009 helps Sponsors and CROs understand how to include the patient viewpoint in the clinical trials that support market authorization for their medical products. The Guidance shows that FDA understands the pivotal role of PRO measures in establishing clinical benefit. This Insights edition is dedicated to ePRO mentioned within the Final Guidance, and intended to provide readers with an executive summary of the new document with respect to ePRO.

FDA PRO Guidance

FDA PRO Guidance

FDA PRO Guidance

Chris Teel Hall

Sponsors and CROs must be assured that clinical data collected for regulatory submissions comply with the regulations and guidance around the world for data quality and integrity. Regulatory agencies are placing more emphasis on the voice of the patient, and they are auditing patient reported data for validity and trustworthiness. Intuitively, capturing patient data electronically instead of on paper would seem capable of providing valid data more reliably and efficiently. PHT has demonstrated that this is true.

How to Safeguard ePRO

How to Safeguard ePRO

How to Safeguard ePRO

Chris Teel Hall

The importance of learning how patients feel and function when taking a new clinical therapy has been acknowledged by the FDA, EMA and other global regulatory authorities. Sponsors currently engaged in drug development programs appreciate and leverage the added value of patient-reported outcome (PRO) data. They no longer ask if PROs should be collected, but what phase to begin PRO collection. This issue of Insights is intended to identify the costs (delays and expenses) of collecting patient-reported outcomes on paper; and compare these against electronic PRO capture. The intention of this issue to provide clinical teams with industry data that can refute the presumption that paper methods are cheaper than ePRO.

When ePRO

Chris Teel Hall

The specialized industry of collecting electronic patient-reported outcomes is increasing linearly, in part because global government regulators want to hear directly from the patient, and because the acceleration and availability of electronic collection (vs. paper collection) improves data quality and efficiencies for data analysis and trial management. This document will review the ePRO market, and outline the five ePRO methods what successfully support the collection of patient-reported data

5 Ways to Collect ePRO

5 Ways to Collect ePRO

5 Ways to Collect ePRO

Chris Teel Hall

Destaque (9)

Temptation

eSource Data and ePRO

eSource Data and ePRO

eSource Data and ePRO

Changing Paradigms - The Evolution of Experiential Production

Changing Paradigms - The Evolution of Experiential Production

Changing Paradigms - The Evolution of Experiential Production

ePRO Archives

$Glenn\'s Production work$ $Glenn\'s Production work$

Glenn\'s Production work

FDA PRO Guidance

FDA PRO Guidance

FDA PRO Guidance

How to Safeguard ePRO

How to Safeguard ePRO

How to Safeguard ePRO

When ePRO

5 Ways to Collect ePRO

5 Ways to Collect ePRO

5 Ways to Collect ePRO